Cargando…

Reduced Expression of Erythropoietin After Intravitreal Ranibizumab in Proliferative Diabetic Retinopathy Patients—Retrospective Interventional Study

Purpose: To evaluate the expressions of erythropoietin (EPO) and vascular endothelial growth factor (VEGF) in the vitreous and fibrovascular membranes (FVMs) of proliferative diabetic retinopathy (PDR) after the intravitreal injection of ranibizumab (IVR) and further explore the relationship between...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Li, Feng, Jing, Shi, Yanhong, Luan, Fuxiao, Ma, Fang, Wang, Yingjie, Yang, Weiqiang, Tao, Yong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8490617/
https://www.ncbi.nlm.nih.gov/pubmed/34621759
http://dx.doi.org/10.3389/fmed.2021.710079
_version_ 1784578550848815104
author Chen, Li
Feng, Jing
Shi, Yanhong
Luan, Fuxiao
Ma, Fang
Wang, Yingjie
Yang, Weiqiang
Tao, Yong
author_facet Chen, Li
Feng, Jing
Shi, Yanhong
Luan, Fuxiao
Ma, Fang
Wang, Yingjie
Yang, Weiqiang
Tao, Yong
author_sort Chen, Li
collection PubMed
description Purpose: To evaluate the expressions of erythropoietin (EPO) and vascular endothelial growth factor (VEGF) in the vitreous and fibrovascular membranes (FVMs) of proliferative diabetic retinopathy (PDR) after the intravitreal injection of ranibizumab (IVR) and further explore the relationship between EPO and VEGF. Method: The concentrations of EPO and VEGF levels in the vitreous fluid were measured in 35 patients (24 PDR and 11 non-diabetic patients) using enzyme-linked immunosorbent assay. The patients were divided into three groups: PDR with IVR (IVR group) before par plana vitrectomy (n = 10), PDR without IVR (Non-IVR group) (n = 14) and a control group [macular holes (MHs) or epiretinal membranes (ERM), n = 11]. Fluorescence immunostaining was performed to examine the expressions of VEGF, EPO and CD 105 in the excised epiretinal membranes. Result: The PDR eyes of Non-IVR group had the highest vitreous VEGF and EPO levels (836.30 ± 899.50 pg/ml, 99.29 ± 27.77 mIU/ml, respectively) compared to the control group (10.98 ± 0.98 pg/ml and 18.96 ± 13.30 mIU/ml/ml). Both the VEGF and EPO levels in the IVR group (13.22 ± 2.72 pg/ml and 68.57 ± 41.47 mIU/ml) were significantly lower than the Non-IVR group (P = 0.004 and P = 0.04, respectively). Furthermore, no significant difference was observed for VEGF levels between the control and IVR groups (10.9 ± 0.98 pg/ml and 13.22 ± 2.72 pg/ml, respectively, P = 0.9). Yet the EPO level in the IVR group was significantly higher than that in the Non-diabetic group (68.57 ± 41.47 pg/ml and 18.96 ± 13.30 pg/ml, respectively, P = 0.001). The expressions of EPO, VEGF, and CD105 were significantly reduced in fluorescence immunostaining of FVMs in the IVR group compared with the Non-IVR group. The receiver operating characteristic (ROC) curve of the EPO and VEGF levels were 0.951 and 0.938 in the PDR group. Conclusion: Both of the VEGF and EPO level were significantly increased in PDR patients, which have equal diagnostic value in the prediction of PDR. IVR could reduce the EPO level, but not enough to the normal level.
format Online
Article
Text
id pubmed-8490617
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-84906172021-10-06 Reduced Expression of Erythropoietin After Intravitreal Ranibizumab in Proliferative Diabetic Retinopathy Patients—Retrospective Interventional Study Chen, Li Feng, Jing Shi, Yanhong Luan, Fuxiao Ma, Fang Wang, Yingjie Yang, Weiqiang Tao, Yong Front Med (Lausanne) Medicine Purpose: To evaluate the expressions of erythropoietin (EPO) and vascular endothelial growth factor (VEGF) in the vitreous and fibrovascular membranes (FVMs) of proliferative diabetic retinopathy (PDR) after the intravitreal injection of ranibizumab (IVR) and further explore the relationship between EPO and VEGF. Method: The concentrations of EPO and VEGF levels in the vitreous fluid were measured in 35 patients (24 PDR and 11 non-diabetic patients) using enzyme-linked immunosorbent assay. The patients were divided into three groups: PDR with IVR (IVR group) before par plana vitrectomy (n = 10), PDR without IVR (Non-IVR group) (n = 14) and a control group [macular holes (MHs) or epiretinal membranes (ERM), n = 11]. Fluorescence immunostaining was performed to examine the expressions of VEGF, EPO and CD 105 in the excised epiretinal membranes. Result: The PDR eyes of Non-IVR group had the highest vitreous VEGF and EPO levels (836.30 ± 899.50 pg/ml, 99.29 ± 27.77 mIU/ml, respectively) compared to the control group (10.98 ± 0.98 pg/ml and 18.96 ± 13.30 mIU/ml/ml). Both the VEGF and EPO levels in the IVR group (13.22 ± 2.72 pg/ml and 68.57 ± 41.47 mIU/ml) were significantly lower than the Non-IVR group (P = 0.004 and P = 0.04, respectively). Furthermore, no significant difference was observed for VEGF levels between the control and IVR groups (10.9 ± 0.98 pg/ml and 13.22 ± 2.72 pg/ml, respectively, P = 0.9). Yet the EPO level in the IVR group was significantly higher than that in the Non-diabetic group (68.57 ± 41.47 pg/ml and 18.96 ± 13.30 pg/ml, respectively, P = 0.001). The expressions of EPO, VEGF, and CD105 were significantly reduced in fluorescence immunostaining of FVMs in the IVR group compared with the Non-IVR group. The receiver operating characteristic (ROC) curve of the EPO and VEGF levels were 0.951 and 0.938 in the PDR group. Conclusion: Both of the VEGF and EPO level were significantly increased in PDR patients, which have equal diagnostic value in the prediction of PDR. IVR could reduce the EPO level, but not enough to the normal level. Frontiers Media S.A. 2021-09-21 /pmc/articles/PMC8490617/ /pubmed/34621759 http://dx.doi.org/10.3389/fmed.2021.710079 Text en Copyright © 2021 Chen, Feng, Shi, Luan, Ma, Wang, Yang and Tao. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Medicine
Chen, Li
Feng, Jing
Shi, Yanhong
Luan, Fuxiao
Ma, Fang
Wang, Yingjie
Yang, Weiqiang
Tao, Yong
Reduced Expression of Erythropoietin After Intravitreal Ranibizumab in Proliferative Diabetic Retinopathy Patients—Retrospective Interventional Study
title Reduced Expression of Erythropoietin After Intravitreal Ranibizumab in Proliferative Diabetic Retinopathy Patients—Retrospective Interventional Study
title_full Reduced Expression of Erythropoietin After Intravitreal Ranibizumab in Proliferative Diabetic Retinopathy Patients—Retrospective Interventional Study
title_fullStr Reduced Expression of Erythropoietin After Intravitreal Ranibizumab in Proliferative Diabetic Retinopathy Patients—Retrospective Interventional Study
title_full_unstemmed Reduced Expression of Erythropoietin After Intravitreal Ranibizumab in Proliferative Diabetic Retinopathy Patients—Retrospective Interventional Study
title_short Reduced Expression of Erythropoietin After Intravitreal Ranibizumab in Proliferative Diabetic Retinopathy Patients—Retrospective Interventional Study
title_sort reduced expression of erythropoietin after intravitreal ranibizumab in proliferative diabetic retinopathy patients—retrospective interventional study
topic Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8490617/
https://www.ncbi.nlm.nih.gov/pubmed/34621759
http://dx.doi.org/10.3389/fmed.2021.710079
work_keys_str_mv AT chenli reducedexpressionoferythropoietinafterintravitrealranibizumabinproliferativediabeticretinopathypatientsretrospectiveinterventionalstudy
AT fengjing reducedexpressionoferythropoietinafterintravitrealranibizumabinproliferativediabeticretinopathypatientsretrospectiveinterventionalstudy
AT shiyanhong reducedexpressionoferythropoietinafterintravitrealranibizumabinproliferativediabeticretinopathypatientsretrospectiveinterventionalstudy
AT luanfuxiao reducedexpressionoferythropoietinafterintravitrealranibizumabinproliferativediabeticretinopathypatientsretrospectiveinterventionalstudy
AT mafang reducedexpressionoferythropoietinafterintravitrealranibizumabinproliferativediabeticretinopathypatientsretrospectiveinterventionalstudy
AT wangyingjie reducedexpressionoferythropoietinafterintravitrealranibizumabinproliferativediabeticretinopathypatientsretrospectiveinterventionalstudy
AT yangweiqiang reducedexpressionoferythropoietinafterintravitrealranibizumabinproliferativediabeticretinopathypatientsretrospectiveinterventionalstudy
AT taoyong reducedexpressionoferythropoietinafterintravitrealranibizumabinproliferativediabeticretinopathypatientsretrospectiveinterventionalstudy